Christine Barker

Sustained remissions with CD19-specific chimeric antigen receptor (CAR)-modified T cells in children with relapsed/refractory ALL.

Shannon L. Maude, David T. Teachey, Susan R. Rheingold et al. · Journal of Clinical Oncology · 2016 · 148 citations

Cell Therapy, T-regulatory Cell, Immunology +20

Efficient Trafficking of Chimeric Antigen Receptor (CAR)-Modified T Cells to CSF and Induction of Durable CNS Remissions in Children with CNS/Combined Relapsed/Refractory ALL

Susan R. Rheingold, Lanyi Nora Chen, Shannon L. Maude et al. · Blood · 2015 · 43 citations

Efficacy and Safety of Humanized Chimeric Antigen Receptor (CAR)-Modified T Cells Targeting CD19 in Children with Relapsed/Refractory ALL

Shannon L. Maude, David M. Barrett, David E Ambrose et al. · Blood · 2015 · 29 citations

Durable Remissions with Humanized CD19-Targeted Chimeric Antigen Receptor (CAR)-Modified T Cells in CAR-Naive and CAR-Exposed Children and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia

Shannon L. Maude, George Hucks, Colleen Callahan et al. · Blood · 2017 · 24 citations

A randomized, multicenter, open-label, phase III study of the Bruton tyrosine kinase (BTK) inhibitor ibrutinib (PCI-32765) versus ofatumumab in patients (pts) with relapsed or refractory (RR) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): RESONATE.

John C. Byrd, Jacqueline C. Barrientos, Stephen Devereux et al. · Journal of Clinical Oncology · 2013 · 14 citations

Rr Cll, Immunology, Immunoediting +16